Pfizer Inc. vs Johnson & Johnson
PFE vs JNJ — side-by-side comparison from reported financials. PFE leads 1, JNJ leads 10 of 11 comparable metrics.
Pfizer Inc.
PFE · Healthcare
$28.27+1.62%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | PFE | JNJ |
|---|---|---|
| Price | $28.27 | $261.79 |
| Market cap | $161B | $631B |
| Revenue (TTM) | $63.7B | $97.9B |
| Revenue growth | -14.8% | +5.6% |
| Net margin | 6.8% | 21.5% |
| Free cash flow | $11.0B | $22.2B |
| Net cash (debt) | ($51.6B) | ($27.8B) |
| 1-year price return | +12.0% | +37.0% |
| P/E | 37.2 | 29.9 |
| P/E vs own history (cheap-side %) | 4% | 16% |
| Dividend yield | 6.07% | 2.00% |
| Return on equity | 5% | 26% |
| Altman Z-score | 1.96 | — |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 75,000 | 140,800 |
Full résumé-style profiles: PFE CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.